☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Drug Safety Update - September 2021

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for September 2021 (PDF).

This issue advises clinicians of rare but severe adverse effects that can occur on stopping treatment with topical corticosteroids. This is more likely after long-term continuous or inappropriate use of moderate to high potency products. To reduce the risks it is recommended that clinicians prescribe the topical corticosteroid of lowest potency needed and ensure patients know how to use it safely and effectively. It is also recommended to:

  • advise patients on the amount of product to be applied; underuse can prolong treatment duration
  • inform patients how long they should use a topical corticosteroid, especially on sensitive areas such as the face and genitals
  • inform patients to return for medical advice if their skin condition worsens while using topical corticosteroid, and advise them when it would be appropriate to re-treat without a consultation
  • for patients currently on long-term topical corticosteroid treatment, consider reducing potency or frequency of application (or both)

Clinicians should also be vigilant for the signs and symptoms of topical steroid withdrawal reactions. The joint statement from the National Eczema Society and British Association of Dermatologists may be useful in guiding practice. And finally, suspected adverse drug reactions should be reported via the Yellow Card scheme, including after discontinuation of topical corticosteroids.

This issue also advises readers of the latest COVID-19 vaccine safety information including data from safety reporting and changes to the Summary of Product Characteristics for some vaccines in regards to storage, precautions and use in 12 to 17 year olds.

Lastly in this issue is a summary of letters to healthcare professionals in August.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'Drug Safety Update - September 2021' on Email Share 'Drug Safety Update - September 2021' on Delicious Share 'Drug Safety Update - September 2021' on Digg Share 'Drug Safety Update - September 2021' on Facebook Share 'Drug Safety Update - September 2021' on reddit Share 'Drug Safety Update - September 2021' on Twitter

SMC Update - September 2021

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Mercaptamine (Procysbi®) has been rejected for the treatment of proven nephropathic cystinosis. The submitting company's justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Amikacin liposomal nebuliser dispersion (Arikayce®) has been rejected for use in the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - September 2021' on Email Share 'SMC Update - September 2021' on Delicious Share 'SMC Update - September 2021' on Digg Share 'SMC Update - September 2021' on Facebook Share 'SMC Update - September 2021' on reddit Share 'SMC Update - September 2021' on Twitter

CKS Updates - August 2021

During August 2021 Clinical Knowledge Summaries were updated in the following areas.

All topics have been reviewed and updated in keeping with current guidance with minor layout changes. The Carpal tunnel syndrome recommendations on follow up in primary care have been amended to reflect pragmatic clinical practice. The Haemorrhoids topic has been updated to recommend that topical preparations for haemorrhoids which should be purchased over the counter in line with NHS Clinical Commissioners (2018). And the Pancreatitis - chronic topic has been updated in line with NICE guidance.

Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.

Share 'CKS Updates - August 2021' on Email Share 'CKS Updates - August 2021' on Delicious Share 'CKS Updates - August 2021' on Digg Share 'CKS Updates - August 2021' on Facebook Share 'CKS Updates - August 2021' on reddit Share 'CKS Updates - August 2021' on Twitter

NICE Guidance - August 2021

The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of August 2021. This month are five guidelines and one COVID-19 rapid guideline that impact upon primary care.

The Bronchiolitis in children: diagnosis and management guideline has been updated. It covers diagnosing and managing bronchiolitis in babies and children. It aims to help healthcare professionals diagnose bronchiolitis and identify if babies and children should be cared for at home or in hospital. The update reviewed the evidence and updated the recommendations on oxygen saturation thresholds for referral to hospital.

The Antenatal care guideline has been published. It covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check‑ups, information and support.

The Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s guideline has been published. It covers the diagnosis and management of obstructive sleep apnoea/hypopnoea syndrome (OSAHS), obesity hypoventilation syndrome (OHS) and chronic obstructive pulmonary disease with OSAHS (COPD-OSAHS overlap syndrome) in people over 16. It aims to improve recognition, investigation and treatment of these related conditions.

The Babies, children and young people's experience of healthcare guideline has been published. It describes good patient experience for babies, children and young people, and makes recommendations on how it can be delivered. It aims to make sure that all babies, children and young people using NHS services have the best possible experience of care.

The Chronic kidney disease: assessment and management guideline has been published, replacing previous guidelines. It covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with chronic kidney disease.

The COVID-19 rapid guideline: managing COVID-19 guideline has been updated. The update corrects an error in the recommended dose of prednisolone for children with a greater than 44-week corrected gestational age.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - August 2021' on Email Share 'NICE Guidance - August 2021' on Delicious Share 'NICE Guidance - August 2021' on Digg Share 'NICE Guidance - August 2021' on Facebook Share 'NICE Guidance - August 2021' on reddit Share 'NICE Guidance - August 2021' on Twitter

Drug Safety Update - August 2021

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for August 2021 (PDF).

This issue advises readers of the latest COVID-19 vaccine safety information including data on menstrual disorders and unexpected vaginal bleeding linked with vaccine administration. It is noted that reporting rates are low, the side effect is usually transient and that there is no evidence to suggest that COVID-19 vaccines will affect fertility and the ability to have children. This section also summarises the available data on the safety of COVID-19 vaccines in pregnancy which has identified no side effect patterns to date. The MHRA will, of course, continue to closely monitor safety data.

Lastly in this issue is a summary of letters to healthcare professionals in July. This includes notification that two desogestrel-containing contraceptive pills have been reclassified as Pharmacy medicines as well as links to recall notifications.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'Drug Safety Update - August 2021' on Email Share 'Drug Safety Update - August 2021' on Delicious Share 'Drug Safety Update - August 2021' on Digg Share 'Drug Safety Update - August 2021' on Facebook Share 'Drug Safety Update - August 2021' on reddit Share 'Drug Safety Update - August 2021' on Twitter

« Older Posts Newer Posts »

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.

vipers